The Diurnal and Nocturnal Effect of Simbrinza and Timolol on Intraocular Pressure and Ocular Perfusion Pressure
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02165631|
Recruitment Status : Completed
First Posted : June 17, 2014
Last Update Posted : March 14, 2016
|Condition or disease|
|Open Angle Glaucoma Ocular Hypertension Pigment Dispersion Syndrome Pseudoexfoliation Glaucoma|
|Study Type :||Observational|
|Actual Enrollment :||60 participants|
|Official Title:||The Diurnal and Nocturnal Effect of Simbrinza and Timolol on Intraocular Pressure and Ocular Perfusion Pressure|
|Study Start Date :||August 2014|
|Actual Primary Completion Date :||March 2016|
|Actual Study Completion Date :||March 2016|
Patients in Group A will receive Simbrinza (brinzolamide) 1%/0.2%, with instruction for three times daily (every 8hours) administration of the medication in both eyes for a minimum of 4 weeks and a maximum of 8 weeks of medication therapy.
Patients in Group B will receive Timolol 0.5%, with instructions for twice daily administration (every 12 hours) of the medication in both eyes for a minimum of 4 weeks and a maximum of 8 weeks of medication therapy.
- Intraocular pressure Group A [ Time Frame: 24 hours ]The primary outcome measure will be the change in intraocular pressure and ocular perfusion pressure after 4 weeks of Simbrinza therapy at multiple time points throughout a 24-hour period.
- Intraocular pressure Group B [ Time Frame: 24 hours ]The secondary outcome measure will be the change in intraocular pressure and ocular perfusion pressure after 4 weeks of timolol therapy at multiple time points throughout a 24-hour period, and how this compares to similar effects by Simbrinza.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02165631
|United States, Colorado|
|University of Colorado Eye Center|
|Aurora, Colorado, United States, 80045|
|Principal Investigator:||Malik Y Kahook, MD||University of Colorado, Denver|